DK0648121T3 - - Google Patents

Info

Publication number
DK0648121T3
DK0648121T3 DK94917283.7T DK94917283T DK0648121T3 DK 0648121 T3 DK0648121 T3 DK 0648121T3 DK 94917283 T DK94917283 T DK 94917283T DK 0648121 T3 DK0648121 T3 DK 0648121T3
Authority
DK
Denmark
Prior art keywords
ring
infection
spiropiperidyl
ring system
rifamycin
Prior art date
Application number
DK94917283.7T
Other languages
Danish (da)
English (en)
Inventor
Jack S Remington
Fausto G Araujo
Original Assignee
Palo Alto Medical Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/203,539 external-priority patent/US5529994A/en
Application filed by Palo Alto Medical Found filed Critical Palo Alto Medical Found
Application granted granted Critical
Publication of DK0648121T3 publication Critical patent/DK0648121T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK94917283.7T 1993-05-05 1994-04-29 DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5728893A 1993-05-05 1993-05-05
US08/203,539 US5529994A (en) 1993-05-05 1994-02-28 Treatment for toxoplasmosis

Publications (1)

Publication Number Publication Date
DK0648121T3 true DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-02-24

Family

ID=26736295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94917283.7T DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-05 1994-04-29

Country Status (14)

Country Link
US (5) US5670496A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0648121B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH07509003A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE143601T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU669300B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2138643A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69400631T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2095772T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3021828T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL109543A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO950030D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2121838C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994025038A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
US6579854B1 (en) 1996-08-14 2003-06-17 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6890526B2 (en) * 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US7074832B2 (en) 2001-09-24 2006-07-11 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US6429231B1 (en) * 2001-09-24 2002-08-06 Bradley Pharmaceuticals, Inc. Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
JP2003327536A (ja) * 2002-03-07 2003-11-19 Kitasato Inst:The ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US6858083B2 (en) * 2002-06-05 2005-02-22 Scimed Lifesystems, Inc. Apparatus and method for closed-loop control of RF generator for welding polymeric catheter components
US20030017985A1 (en) * 2002-07-02 2003-01-23 Taylor Gregory Alan Molecules that influence pathogen resistance
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
TW201233389A (en) 2005-10-05 2012-08-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
US7799885B2 (en) 2005-11-30 2010-09-21 Corning Incorporated Photo or electron beam curable compositions
US20090054380A1 (en) * 2005-12-20 2009-02-26 Greenstein Robert J Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
SG10201405158QA (en) * 2006-02-24 2014-10-30 Callida Genomics Inc High throughput genome sequencing on dna arrays
RU2320337C1 (ru) * 2006-06-09 2008-03-27 Федеральное государственное унитарное предприятие "Государственный научный центр по антибиотикам" Способ получения антимикробной композиции с рифабутином
FR2944014A1 (fr) 2009-04-06 2010-10-08 Univ Grenoble 1 Peptides cycliques a activite antiparasitaire
CN114601840A (zh) * 2020-12-08 2022-06-10 复旦大学附属中山医院 一种联合用药,用于治疗卡氏肺孢子虫肺炎
CN113230248A (zh) * 2021-06-18 2021-08-10 宁波大学 利卡灵-b及其组合物在制备治疗或预防弓形虫病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644616A (en) * 1969-03-24 1972-02-22 Ciba Geigy Corp Synergistic composition of rifampicin and streptomycin
US4054663A (en) * 1974-12-23 1977-10-18 Sankyo Company Limited Pyridine derivatives and their use as anticoccidial agents
US4094982A (en) * 1975-05-15 1978-06-13 Sankyo Company Limited Pyridine sulfonamides and their use as anticoccidial agents
IT1056272B (it) * 1975-06-13 1982-01-30 Archifar Ind Chim Trentino Prodotti derivati dalle amine aromatiche
IT1135270B (it) * 1980-04-12 1986-08-20 Erba Farmitalia 3-amidino-ansamicine
US5175319A (en) * 1983-04-14 1992-12-29 Burroughs Wellcome Co. Naphthoquinone derivatives
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
DE3512194A1 (de) * 1985-04-03 1986-10-09 Hoechst Ag, 6230 Frankfurt Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
GB9000241D0 (en) * 1990-01-05 1990-03-07 Coopers Animal Health Pharmaceutical use
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis

Also Published As

Publication number Publication date
CA2138643A1 (en) 1994-11-10
AU669300B2 (en) 1996-05-30
RU2121838C1 (ru) 1998-11-20
ATE143601T1 (de) 1996-10-15
US5648345A (en) 1997-07-15
US5670496A (en) 1997-09-23
WO1994025038A1 (en) 1994-11-10
US5665707A (en) 1997-09-09
NO950030L (no) 1995-01-04
US5641769A (en) 1997-06-24
ES2095772T3 (es) 1997-02-16
IL109543A (en) 1998-06-15
DE69400631T2 (de) 1997-02-27
EP0648121A1 (en) 1995-04-19
IL109543A0 (en) 1994-08-26
EP0648121B1 (en) 1996-10-02
DE69400631D1 (de) 1996-11-07
RU95105973A (ru) 1997-01-20
GR3021828T3 (en) 1997-02-28
AU6905094A (en) 1994-11-21
JPH07509003A (ja) 1995-10-05
NO950030D0 (no) 1995-01-04
US5650405A (en) 1997-07-22

Similar Documents

Publication Publication Date Title
DK0648121T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU653415B2 (en) Method of treating ocular inflammation
MX9707732A (es) Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.
PH31610A (en) Taxol derivatives.
IL98258A0 (en) Composition for treating impotence containing doxazosin,amlodipine,or u.k.52,046
AU6710598A (en) Improved methods for the determination and adjustment of prolactin daily rhythms
MY106263A (en) Method for the treatment or prevention of intrinsically aged skin with retinoids
AU7578994A (en) Methods for inhibiting cartilage degradation
IE841494L (en) Androsta-1,4-diene-3,17-diones
HUT71421A (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU7210491A (en) Method and device for continuously treating of fuel
CA2188871A1 (en) Method for Treating Psoriasis
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
NZ336249A (en) parenteral composition of a dihydropolyprenol and a pharmaceutically acceptable oil
AU6218190A (en) Letterpress for transferring and method of transferring by use of the letterpress for transferring
CA2080040A1 (en) Methods for preventing mycobacterial infections by administration of rifabutin
AU6112394A (en) Vinca alkaloids for the treatment of papillomavirus infection
UA66809C2 (uk) Спосіб лікування гіперглікемії похідною тіазолідиндіону
GR3030255T3 (en) Methods of reducing scarring in wound healing
AU3887789A (en) Method for suppressing immune responses by administering imexon
AU7237491A (en) A method of treating a mammal with a biologically active compound
UA10436A (uk) Спосіб лікуваhhя виразкової хвороби шлуhку та дваhадцятипалої кишки
TW343973B (en) Morphinan derivative and medical use